Indaptus Therapeutics (INDP) Competitors $10.67 -0.15 (-1.39%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock INDP vs. MBRX, TPST, CING, DARE, PULM, GDTC, ELEV, AYTU, LSTA, and NAIIShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Moleculin Biotech (MBRX), Tempest Therapeutics (TPST), Cingulate (CING), Dare Bioscience (DARE), Pulmatrix (PULM), CytoMed Therapeutics (GDTC), Elevation Oncology (ELEV), Aytu BioPharma (AYTU), Lisata Therapeutics (LSTA), and Natural Alternatives International (NAII). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Its Competitors Moleculin Biotech Tempest Therapeutics Cingulate Dare Bioscience Pulmatrix CytoMed Therapeutics Elevation Oncology Aytu BioPharma Lisata Therapeutics Natural Alternatives International Moleculin Biotech (NASDAQ:MBRX) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Does the media refer more to MBRX or INDP? In the previous week, Moleculin Biotech had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 3 mentions for Moleculin Biotech and 0 mentions for Indaptus Therapeutics. Moleculin Biotech's average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score. Company Overall Sentiment Moleculin Biotech Neutral Indaptus Therapeutics Neutral Do institutionals & insiders hold more shares of MBRX or INDP? 15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 2.1% of Moleculin Biotech shares are owned by insiders. Comparatively, 20.8% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is MBRX or INDP more profitable? Moleculin Biotech's return on equity of -278.80% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -278.80% -100.11% Indaptus Therapeutics N/A -333.02%-216.36% Which has more risk and volatility, MBRX or INDP? Moleculin Biotech has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Which has stronger valuation and earnings, MBRX or INDP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$21.76MN/AN/AIndaptus TherapeuticsN/AN/A-$15.02M-$41.74-0.26 Do analysts recommend MBRX or INDP? Moleculin Biotech currently has a consensus target price of $4.00, suggesting a potential upside of 464.25%. Indaptus Therapeutics has a consensus target price of $238.00, suggesting a potential upside of 2,130.55%. Given Indaptus Therapeutics' higher probable upside, analysts clearly believe Indaptus Therapeutics is more favorable than Moleculin Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMoleculin Biotech beats Indaptus Therapeutics on 5 of the 8 factors compared between the two stocks. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.11M$2.50B$5.66B$9.45BDividend YieldN/A1.80%4.01%4.02%P/E Ratio-0.269.1428.0720.12Price / SalesN/A601.79417.5199.64Price / CashN/A165.2635.9658.29Price / Book0.985.178.555.81Net Income-$15.02M$30.99M$3.24B$258.18M7 Day Performance-8.29%4.88%4.86%3.98%1 Month Performance-23.79%16.58%13.00%14.81%1 Year Performance-82.02%0.23%35.57%19.30% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics2.6989 of 5 stars$10.67-1.4%$238.00+2,130.6%-82.3%$6.11MN/A-0.266MBRXMoleculin Biotech2.4738 of 5 stars$0.78-2.5%$4.00+411.5%-80.8%$23.62MN/A0.0020News CoverageGap UpTPSTTempest Therapeutics1.6433 of 5 stars$6.31-0.5%$30.00+375.4%-74.2%$23.24MN/A-0.3520CINGCingulate2.8216 of 5 stars$5.44-3.9%$26.00+377.9%+1,658.2%$23.12MN/A-0.6420DAREDare Bioscience1.3686 of 5 stars$2.60-3.2%$12.00+362.4%-29.3%$22.97M$25.91K-15.2630Gap UpPULMPulmatrixN/A$6.20+2.1%N/A+204.0%$22.63M$1.92M-1.8620GDTCCytoMed Therapeutics1.4853 of 5 stars$2.04+2.0%$5.00+145.1%-6.0%$22.32M$69.50K0.00N/AUpcoming EarningsELEVElevation Oncology2.3529 of 5 stars$0.38+0.6%$3.39+802.9%-86.5%$22.21MN/A-0.4640News CoverageAYTUAytu BioPharma3.7735 of 5 stars$2.48+4.5%$10.00+303.9%-7.6%$22.13M$81.66M-3.42160Positive NewsLSTALisata Therapeutics2.7859 of 5 stars$2.56-1.0%$23.50+819.8%-25.4%$22.02M$1M-1.1130Gap DownNAIINatural Alternatives International0.6422 of 5 stars$3.55+5.7%N/A-40.1%$21.94M$113.80M-2.55290Positive News Related Companies and Tools Related Companies MBRX Alternatives TPST Alternatives CING Alternatives DARE Alternatives PULM Alternatives GDTC Alternatives ELEV Alternatives AYTU Alternatives LSTA Alternatives NAII Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INDP Stock Alerts